PBAC's latest decision on Ezetimibe + atorvastatin: Recommended (2014). Considered for Treatment of hypercholesterolaemia in patients with inadequately controlled cholesterol on statin monotherapy, or those with homozygous familial hypercholesterolaemia.
PBAC outcome
Recommended
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2014
Submissions
1
2014 → 2014
Eligible population
Patients with hypercholesterolaemia inadequately controlled with a statin, or those with homozygous familial hypercholesterolaemia, including those with coronary heart disease, diabetes mellitus, peripheral vascular disease, heterozygous familial hypercholesterolaemia, cerebrovascular disease, family history of coronary heart disease, or hypertension.
Therapy area
Cardiovascular
Line of therapy
Second-line
Evidence base
Single-arm
Primary endpoint
Cost-minimisation
Key trials
P391, P392
Comparator
ezetimibe + atorvastatin co-pack and individual components taken concomitantly
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis performed; no ICER calculated by design.